Keywords: impax, comments, rilutek, generic, ruling, laboratories, usa
Impax comments on Rilutek generic ruling
Article | 06 September 2004
Impax Laboratories of the USA says that the District Court ofWilmington, Delaware, has ruled that Aventis Pharmaceutical's patent 5,527,814 related to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
